DNA

Safety Shot Provides Update on Expected Closing of Yerbaé Brands Corp. Acquisition

SCOTTSDALE, AZ, June 20, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today provided…

6 months ago

DARZALEX® (daratumumab) receives the first positive CHMP opinion for patients with high-risk smouldering multiple myeloma

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing…

6 months ago

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”)…

6 months ago

Pioneering precision: GE HealthCare aims to elevate clinical care through total body PET/CT technology with Stanford Medicine

GE HealthCare and the Department of Radiology at Stanford Medicine aim to explore total body positron emission tomography/computed tomography (PET/CT)…

6 months ago

Pioneering precision: GE HealthCare aims to elevate clinical care through total body PET/CT technology with Stanford Medicine

GE HealthCare and the Department of Radiology at Stanford Medicine aim to explore total body positron emission tomography/computed tomography (PET/CT)…

6 months ago

Catholic Health Teams Up with Olympic Gold Medalist Katie Ledecky to Help Patients Optimize Their Health

As Health & Wellness Ambassador at Catholic Health, Ledecky channels her Olympic mindset to educate Long IslandersROCKVILLE CENTRE, N.Y., June 19,…

6 months ago

Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board

-  Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation -  Following…

6 months ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results…

6 months ago

Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

- First patient received bilateral administration of NRTX-1001; no significant surgical complications or adverse events reported to date - -…

6 months ago